Info

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company has developed a technology that enables it to manufacture active immunotherapy products that are designed to stimulate a patient’s immune system to mount a specific and sustained response to disease. Favrille's lead product candidate, Specifid (mitumprotimut-T, formerly FavId), is an active immunotherapy for the treatment of B-cell non-Hodgkin’s lymphoma (NHL). In June 2007, Favrille, Inc. announced that it acquired a series of optimized anti-CD20 monoclonal antibodies from Diversa Corporation.(Source: 10-K)